Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Effects of Ileal UDCA Delivery
NCT03201952Phase 1Terminated
- Sponsor
- Vanderbilt University Medical Center
- Start
- Feb 2018
- Primary completion
- May 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ursodeoxycholic acid in glucose intolerance (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Change in glucose level at 3 hours. Started Feb 2018; status: terminated.
02
Drugs
ursodeoxycholic acid
03
Conditions
glucose intolerance
Beyond the preview
Go deeper on NCT03201952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03201952.